Like normal no news on any front - but hey they are working hard at doing nothing so what would we expect.
So far non of the next steps as listed in the investor presentation issued om 15 August 2017 delivered
ZolpiMist master license deal in Europe ✓
Further partnering deals with SUDA’s other candidates ✓
Monetisation of ArTiMist ✓
Expansion of Pfizer collaboration ✓
Early sales success for TEVA with ZolpiMist ✓
Expansion of TEVA markets ✓
Approval of ZolpiMIst in Australia and Europe
So I dont have to go back over three years
Ann: New Analyst Report, page-25
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.010(5.41%) |
Mkt cap ! $205.1M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 20.0¢ | 18.5¢ | $867.7K | 4.443M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 650036 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 181193 | 6 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| ALA (ASX) Chart |